Allogeneic stem cell transplant (allo-SCT) recipients are predisposed to infection by a variety of opportunistic pathogens. Recipients of T-cell-depleted allografts and patients with graft-versus-host disease (GVHD) may have more extensive and prolonged T-cell immunodeficiency, associated with a heightened risk for severe infection. We previously reported high rates of infection and colonization by nontuberculous mycobacteria (NTM) at our center, where approximately two-thirds of allografts are T-cell depleted. 1 Here we extend that analysis and report a high rate of tuberculosis (TB) infection confined exclusively to patients from TB endemic regions.
TB is a well-described pathogen among allo-SCT recipients and varies in frequency from 0 to 0.2% in reports from allo-SCT centers in the United States to 4% in reports from TB endemic regions.
2-8 However, the prevalence of active TB after allo-SCT has not been reported for patients born in TB endemic regions who undergo allo-SCT at centers in the United States or Western Europe. To guide TB screening and therapy at our center, we sought to determine whether patient-specific factors would define a subset of allo-SCT recipients at high risk for active TB.
Memorial Sloan-Kettering Cancer Center (MSKCC) is a 434-bed tertiary-care cancer hospital in New York City. Records were retrieved from the allo-SCT database and medical charts for patients X18 years old who underwent allo-SCT between January 1993 and December 2001. T-cell depletion was performed by either soybean agglutination followed by rosetting with sheep red blood cells, T 10 B 9 -1A3, or Isolex 300i. Tuberculin skin testing (TST) is not routinely performed prior to allo-SCT, and prophylactic antibiotics (eg ciprofloxacin) are not given prior to or after allo-SCT. Mycobacterial specimens were stained with the auramine acid-fast stain and cultured on Middlebrook 7H11 agar.
Over the study period, 577 patients underwent allo-SCT at our center, of which 372 (64.4%) received T-cell-depleted allografts. Four (0.69%) patients developed active TB (three culture positive and one by clinical diagnosis) and are described in Table 1 . In comparison, 50/577 (8.7%) patients had positive cultures for NTM and 34/577 (5.9%) developed definite or probable NTM infections. Two of the TB cases received T-cell-depleted allografts, while the other two patients developed acute GVHD after T-cell replete allo-SCTs and required cyclosporine and systemic corticosteroids prior to developing active TB. When divided by country of origin, 4/92 foreign-born (4.4%) and 0/485 US-born allo-SCT recipients developed active TB after transplant (Po0.05). None of the four TB cases had a known TB exposure or a positive TST prior to allo-SCT (Table 1) .
All isolates were sensitive to first-line anti-TB medications. The three patients who received anti-TB antimicrobials were cured without side effects and remain alive. No secondary TB cases were identified. Overall survival was significantly longer for patients with TB infection than those with positive cultures for NTM (Po0.05; Figure 1 ). In contrast with reports of atypical TB among patients with HIV, 9 the four allo-SCT recipients presented with common findings for active TB. Case 1 presented 75 days after allo-SCT with Pseudomonas aeruginosa sepsis. Her chest X-ray showed a miliary pattern. She died 9 days later and a tracheal aspirate from the day of admission grew TB. Patient #2 developed a mass in his right neck with no other symptoms 10 months after T-cell-depleted allo-SCT. A biopsy showed caseating granulomas with acid-fast bacilli and a culture grew TB. Patient #3 developed persistent, culture-negative fevers approximately 60 days after T-celldepleted allo-SCT. CT scan of the chest showed a right upper lobe nodule. Lung biopsy revealed necrotizing granulomas. AFB smear was positive and cultures grew TB. Patient #4 developed fevers and productive cough 6 months after allo-SCT. Chest X-ray showed bilateral upper lobe infiltrates and a linear scar with calcifications in the left mid-lung field. He was treated with broad-spectrum antibiotics. Open-lung biopsy showed noncaseating granulomas. All stains and cultures were negative. He received TB-directed antibiotics and his infiltrates resolved. Similar to previous reports, all infections were diagnosed 460 days after allo-SCT and outcomes for patients who received TB-directed therapy was good. 4, 10 The overall prevalence of TB among allo-SCT recipients at out center was 4/577 (0.69%), similar to reports from other centers in regions with low rates of TB in the general population. 7, 8, 10 However, the prevalence among US-born patients was 0/465 (0%), despite concurrent outbreaks of TB among AIDS patients in the New York City area. Active TB occurred exclusively among the cohort of allo-SCT recipients who were (1) from TB endemic regions and (2) either received T-cell-depleted allografts or required systemic corticosteroids for GVHD. We estimate that approximately 40 of the 577 allo-SCT recipients fall into this group. Among these patients, the prevalence of TB after allo-SCT was B10%, a rate similar to or higher than that reported from centers in TB endemic regions. 6, 10 Overall, 20% (4/20) of foreign-born patients with positive mycobacterial cultures had TB compared to 0% (0/34) of US-born patients (Po0.05).
The approach to latent TB infection (LTBI) among potential allo-SCT recipients varies markedly between centers. 4 The diagnosis of LTBI is difficult in immunocompromised patients, as they are likely to have attenuated responses to TST.
2 In addition, TB-directed antimicrobials (eg isoniazid, rifampin) are associated with hepatotoxicity allo-SCT, we strongly consider empiric isoniazid for LTBI in patients from TB endemic regions prior to or immediately after allo-SCT (beginning day þ 30), regardless of TST status. The role of newer assays for diagnosing LTBI remains to be determined in allo-SCT recipients. Finally, allo-SCT recipients from TB endemic regions with pulmonary syndromes should be isolated until the diagnosis of TB has been excluded. 
